Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997597 | PMC |
| http://dx.doi.org/10.1080/13543784.2022.2108588 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.
Expert Opin Investig Drugs
September 2022
Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
Clin Cancer Res
January 2020
Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Purpose: Advances in immunotherapy have revolutionized care for some patients with cancer. However, current checkpoint inhibitors are associated with significant toxicity and yield poor responses for patients with central nervous system tumors, calling into question whether cancer immunotherapy can be applied to glioblastoma multiforme. We determined that targeting the CD200 activation receptors (CD200AR) of the CD200 checkpoint with a peptide inhibitor (CD200AR-L) overcomes tumor-induced immunosuppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!